Close Menu
Simply Invest Asia
  • Home
  • About us
  • Explore industries/sectors
    • Automobile
    • Aviation
    • Banking
    • Biotechnology
    • Chemical & Fertilizer
    • Entertainment and Media
    • Food Processing
    • Healthcare
    • Iron and Steel
    • Leather
    • Mining
    • Oil and Gas
    • Pharmaceutical
  • Explore by countries
    • China
    • Dubai / UAE
    • Hong Kong
    • India
    • Indonesia
    • Japan
    • Malaysia
  • Explore cities
    • Bangkok
    • Beijing
    • Chongqing
    • Delhi
    • Dubai
    • Guangzhou
    • Jakarta
    • Kuala Lumpur
  • Why Asia
Facebook X (Twitter) Instagram Threads
Trending:
  • India’s gig economy leaving its women behind, study finds
  • Thousands in Indonesia pray for rain amid forest fires
  • Vedanta Iron And Steel, Vedanta Power: How Vedanta Group stocks are performing as benchmarks fall
  • Barclays expects China to broaden offshore wealth curbs, but Hong Kong remains resilient
  • Chinese micro-dramas race onto global stage-Xinhua
  • Reconciling agriculture, nature and rural development in China and the Netherlands
  • Syria: Violence Against Health Care in Conflict 2025 [EN/AR] – Syrian Arab Republic
  • Japan’s first commercial-scale liquefied hydrogen terminal chooses its DCS control system
  • Global Bakery Depanners Market — Analysis of Key Trends, Regional Growth, Top Players, and a 10-year Forecast from 2026 to 2036
  • Dubai’s new wave of wellness clubs
  • China’s Xi welcomes Jordan’s King Abdullah II in Beijing – AP News
  • Zee Entertainment receives ₹659.76 crore from promoter entity for preferential issue of fully convertible warrants
  • Anger as it emerges Welsh Government met Indian arms firm linked to Israel
  • Six-firm consortium wins Northern Metropolis tender for HK$1.03b
  • Melrose Industries to launch $100m claims programme after chemical incident at US site – date set for return of full manufacturing operations
  • Inspirational Filipino Para-Athletes Compete in HYROX Bangkok – Metro.Style
  • Recognise Bank completes £1.836m bridging loan for Harlow site acquisition – The Intermediary
  • mRNA Cancer Vaccine Trial Succeeds, Biotech Sector Sees Catalyst
Tuesday, August 25
Facebook X (Twitter) Instagram
Simply Invest Asia
  • Home
  • About us
  • Explore industries/sectors
    • Automobile
    • Aviation
    • Banking
    • Biotechnology
    • Chemical & Fertilizer
    • Entertainment and Media
    • Food Processing
    • Healthcare
    • Iron and Steel
    • Leather
    • Mining
    • Oil and Gas
    • Pharmaceutical
  • Explore by countries
    • China
    • Dubai / UAE
    • Hong Kong
    • India
    • Indonesia
    • Japan
    • Malaysia
  • Explore cities
    • Bangkok
    • Beijing
    • Chongqing
    • Delhi
    • Dubai
    • Guangzhou
    • Jakarta
    • Kuala Lumpur
  • Why Asia
Simply Invest Asia
Home»Explore industries/sectors»Biotechnology»One NASDAQ- Listed Biotechnology Stock at Resistance Level – SRPT
Biotechnology

One NASDAQ- Listed Biotechnology Stock at Resistance Level – SRPT

By IslaJuly 9, 20264 Mins Read
Share
Facebook Twitter Pinterest Threads Bluesky Copy Link


Sarepta Therapeutics (NASDAQ: SRPT) is a commercial-stage biopharmaceutical company focused on developing RNA-targeted, siRNA, gene therapy, and other genetic medicines for rare diseases. It is best known for its Duchenne muscular dystrophy portfolio, with four approved products: EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, while also advancing therapies for LGMD and other neuromuscular and CNS disorders. 

According to our previous US Dailies Report published on ‘SRPT’ on June 18, 2026, Kalkine recommended a ‘Speculative Buy’ stance on the stock at USD 16.96. This recommendation was based on fundamental analysis, and the stock has now surged by 16.69%, trading near the second resistance level.

Noted below are the details of technical summary provided in our previous report:


Disclaimer-

This report (“Report”) has been issued by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and prepared by Kalkine and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any advice provided in this Report is general advice only and does not take into account your objectives, financial situation or needs. You should therefore consider whether the advice is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred in this Report. You should obtain a copy of the relevant Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any of the general advice in this Report or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Report and on the Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its reports (including this Report), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Report does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products. Our reports contain general recommendations to invest in securities and other financial products. Kalkine is not responsible for, and does not guarantee, the performance of, or returns on, any investments mentioned in this Report.

Kalkine does not issue, sell or deal in any financial products.

This Report may contain information on past performance of particular investments. Past performance is not a reliable indicator of future performance. Returns stated do not take into account transaction costs and taxes. To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Report, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you.  To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information. Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Report or on the Kalkine website. Any such employees and associates are required to comply with certain, procedures and disclosures as required by law.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website including entities covered in this Report.

Copyright 2026 Krish Capital Pty. Ltd. (ABN 61629651510). All Rights Reserved. No part of this report, or its content, may be reproduced in any form without our prior consent.

Past performance is not a reliable indicator of future performance.



Source link

Related Posts

mRNA Cancer Vaccine Trial Succeeds, Biotech Sector Sees Catalyst

August 25, 2026

Biotech Breakout: What's in focus after Moderna's cancer win? (MRNA:NASDAQ) – Seeking Alpha

August 24, 2026

AI Bioreactor Controls Market Size 2036

August 24, 2026
Add A Comment
Leave A Reply Cancel Reply

Top Posts

China Scraps 12,000 Degrees in Biggest Academic Overhaul in Years

June 14, 2026

Aviation brigade conducts aerial refueling training

July 1, 2026

Chinese Wall may stem India tech flows for electronics and automobile

June 1, 2026
Don't Miss

India’s gig economy leaving its women behind, study finds

By IslaAugust 25, 2026

Women workers are underrepresented in jobs at companies such as Uber Technologies, Swiggy and Urban…

Thousands in Indonesia pray for rain amid forest fires

August 25, 2026

Vedanta Iron And Steel, Vedanta Power: How Vedanta Group stocks are performing as benchmarks fall

August 25, 2026

Barclays expects China to broaden offshore wealth curbs, but Hong Kong remains resilient

August 25, 2026
SUBSCRIBE TO OUR NEWSLETTER

Get our latest downloads and information first. Complete the form below to subscribe to our weekly newsletter.


I consent to being contacted via telephone and/or email and I consent to my data being stored in accordance with European GDPR regulations and agree to the terms of use and privacy policy.

Stay In Touch
  • Facebook
  • YouTube
  • TikTok
  • WhatsApp
  • Twitter
  • Instagram
Top Trending

Anger as it emerges Welsh Government met Indian arms firm linked to Israel

By IslaAugust 25, 2026

Six-firm consortium wins Northern Metropolis tender for HK$1.03b

By IslaAugust 25, 2026

Melrose Industries to launch $100m claims programme after chemical incident at US site – date set for return of full manufacturing operations

By IslaAugust 25, 2026
Most Popular

India’s Precious Moment | The Voice Of Fashion

April 16, 2026

Chinese, ROK business leaders gather in Guangzhou to boost cooperation

May 29, 2026

China and DPRK eye closer party ties, cooperation

July 18, 2026
Our Picks

Firefly Now Targeting Next Alpha Flight By Year’s End

August 11, 2026

VOXX BKK highlights Bangkok’s shrinking living spaces in new campaign for Homerun Proptech – Campaign Brief Asia

June 10, 2026

Gov't defends Kenya’s GMO approval process, says it meets global standards – Citizen Digital

June 5, 2026
SUBSCRIBE TO OUR NEWSLETTER

Get our latest downloads and information first. Complete the form below to subscribe to our weekly newsletter.


I consent to being contacted via telephone and/or email and I consent to my data being stored in accordance with European GDPR regulations and agree to the terms of use and privacy policy.

© 2026 Simply Invest Asia.
  • Get In Touch
  • Cookie Policy
  • Privacy policy
  • Terms & Conditions

Type above and press Enter to search. Press Esc to cancel.

SUBSCRIBE TO OUR NEWSLETTER

Get our latest downloads and information first.

Complete the form below to subscribe to our weekly newsletter.


I consent to being contacted via telephone and/or email and I consent to my data being stored in accordance with European GDPR regulations and agree to the terms of use and privacy policy.